Arcitumomab Biosimilar – Anti-CEACAM5, CD66e mAb – Research Grade

Description of Arcitumomab Biosimilar - Anti-CEACAM5, CD66e mAb - Research Grade

Title: Understanding the Structure and Function of Arcitumomab Biosimilar – Anti-CEACAM5, CD66e mAb

Introduction:

Arcitumomab Biosimilar – Anti-CEACAM5, CD66e mAb is a monoclonal antibody that has been developed as a biosimilar to the original Arcitumomab antibody. It is designed to target the carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), also known as CD66e, which is a protein found on the surface of many cancer cells. In this article, we will explore the structure, activity, and potential applications of this biosimilar in scientific research.

Structure:

Arcitumomab Biosimilar is a recombinant monoclonal antibody that is produced in Chinese hamster ovary (CHO) cells. It is composed of two identical heavy chains and two identical light chains, which are connected by disulfide bonds. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains have two constant domains (CL and CL2) and one variable domain (VL). The variable domains of both heavy and light chains are responsible for binding to the specific target, CEACAM5.

Activity:

Arcitumomab Biosimilar binds specifically to CEACAM5, a glycoprotein that is overexpressed in various types of cancer, including colorectal, breast, and lung cancer. This binding occurs through the variable domains of the antibody, which recognize and bind to specific regions on the CEACAM5 protein. This binding triggers a series of events that lead to the destruction of the cancer cells, either by activating the body’s immune system or by directly inhibiting the growth and survival of the cancer cells.

Application:

The primary application of Arcitumomab Biosimilar is in the field of cancer research. Its ability to target and bind to CEACAM5 makes it a valuable tool for studying the role of this protein in different types of cancer. It can also be used to investigate the efficacy of other potential cancer therapies that target CEACAM5. Additionally, Arcitumomab Biosimilar can be used in diagnostic imaging, as it has been labeled with a radioactive isotope to detect the presence of CEACAM5 in cancer cells.

Therapeutic Potential:

Apart from its use in research, Arcitumomab Biosimilar also has therapeutic potential. It has been shown to be effective in clinical trials for the treatment of colorectal cancer, both as a standalone treatment and in combination with other chemotherapy drugs. Its ability to specifically target CEACAM5 makes it a promising option for targeted cancer therapy, which aims to minimize the side effects of traditional chemotherapy.

Conclusion:

In summary, Arcitumomab Biosimilar – Anti-CEACAM5, CD66e mAb is a recombinant monoclonal antibody that targets the cancer-associated protein CEACAM5. Its structure consists of two heavy chains and two light chains, and its activity involves binding to CEACAM5 and triggering the destruction of cancer cells. This biosimilar has potential applications in cancer research and therapy, and its development marks a significant advancement in the field of targeted cancer treatment.

Arcitumomab Biosimilar - Anti-CEACAM5, CD66e mAb binds to CD66e Recombinant Protein in indirect ELISA Assay

Immobilized CD66e Recombinant Protein (cat. No.PX-P4089) at 0.5µg/mL (100µL/well) can bind to Arcitumomab Biosimilar - Anti-CEACAM5, CD66e mAb (cat. No.PX-TA1077) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450